Invesco Dorsey Wright Healthcare Momentum ETF (PTH)

COPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Company's Phase 2 PaTH Forward and Phase 3 PaTHway trials. The data, which confirm results for each individual trial presented at major endocrinology meetings earlier this year, were shared during Kidney Week 2025 in a poster presented by lead author Dr. Elvira Gosmanova, a nephrologist at Albany Medical College and Albany VAMC (New York).

COPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium handling, and continued safety and efficacy in adults with hypoparathyroidism treated with TransCon PTH (palopegteriparatide) through Year 3 of the Phase 2 PaTH Forward and Phase 3 PaTHway trials will be shared during Kidney Week 2025, the annual meeting of the American Society for Nephrology being held in Houston from November 5-9. ThursdayNovember 610 a.m.

COPENHAGEN, Denmark, July 14, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 156 of its Phase 3 PaTHway Trial confirming that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism regardless of its cause (post-surgical, autoimmune, genetic, or idiopathic), including improvements in biochemistries, kidney function, and quality of life. Results were shared over the weekend in an oral presentation by Aliya Khan, M.D.

COPENHAGEN, Denmark, May 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced new data from Week 214 of its Phase 2 PaTH Forward Trial showing that long-term treatment with TransCon PTH (palopegteriparatide) continued to provide a durable response in adults with hypoparathyroidism. Results were shared in an oral presentation today by Andrea Palermo, M.D., from the Campus Bio-Medico University (Rome), during ESPE & ESE 2025, the joint congress of the European Society for Paediatric Endocrinology (ESPE) and the European Society of Endocrinology (ESE).

PTH is comprised of 30+ Health Care stocks selected based on a proprietary momentum-based model. Its expense ratio is 0.60% and the ETF has $115 million in assets under management. The strategy relies on technical analysis, but that's not necessarily the issue. Instead, PTH reconstitutes quarterly, forcing managers to wait to buy stocks only after they've made their massive gains. PTH's current holdings illustrate this point perfectly. Although they've gained 51% over the last six months, the ETF itself has declined by 12% over the same period.

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today announced its decision to discontinue the Phase 1 single- and multiple-ascending dose (SAD/MAD) clinical trial of SEP-786 in healthy volunteers.

The current dip has made many ETFs attractive, and we call them "Secret Santa." These could surprise investors with big returns this Christmas.

COPENHAGEN, Denmark, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) shared 3-year results from the Company's ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon™ PTH (palopegteriparatide; marketed as YORVIPATH®) through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population.1,2,3,4 In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency.

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

PTH tracks the DWA Healthcare Technical Leaders Index, selecting U.S. Health Care stocks based on a proprietary relative strength measure. There are about 300 U.S. Health Care stocks in the selection universe. The Index only requires 30, and any point, you'll see many early-stage firms delivering exceptional short-term returns. As a result, PTH holds mostly small-cap stocks with huge recent price gains. However, the flaw is its passively-managed approach that rebalances and reconstitutes on a fixed quarterly timeline.

The Nasdaq Composite and the S&P 500 hit new all-time high Friday. However, there are chances of further rally.

In a somewhat surprising turn, biotech and life sciences-focused ETFs were the driving themes in the last week's top-performing ETFs, with the ALPS Medical Breakthroughs ETF (SBIO) leading the way with a 10% return.

Sector ETF report for PTH

How a recession could impact health care stocks in 2023. As Covid continues, what it could mean for the health care sector.